Catalent announced further cuts at its Bloomington, Indiana site, as the global CDMO continues to adjust to a post-pandemic environment.
The 150 job cuts will mostly be leadership and support positions, Catalent told employees earlier this week. The layoffs will eliminate duplication and operational inefficiencies.
A company spokesperson told the Herald-Times that global demand for vaccines declined sharply as the pandemic receded, requiring the company to make adjustments.
“Unfortunately we didn’t anticipate the unprecedented complexity involved in exiting the pandemic, both operationally and financially, and the difficulty of pivoting this site to non-COVID programs,” said Anibal Carlo, vice president and general manager of the Bloomington facility.
Catalent played a major role in COVID vaccine manufacturing efforts, signing deals with AstraZeneca, J&J and Moderna. But adjusting its infrastructure to a post-pandemic world has not come easy. Late last year, Catalent announced that it would be letting go of 400 employees at the same Bloomington site. Prior to that, the company announced structural changes and cost-reduction measures including more than 200 layoffs in its Texas and Maryland facilities.
